- Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: Albuterol 25 mcg, Placebo; Drug: Albuterol 0.25 mcg; Drug: Albuterol 90 mcg, Placebo; Drug: Albuterol, 90 mcg; Drug: Placebo; Drug: Proventil 90 mcg; Drug: Proventil 90 mcg
Sponsors: Amphastar Pharmaceuticals, Inc.; Amphastar Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF; Drug: FF/VI
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Mild to Moderate Atopic Dermatitis
Intervention: Drug: HL-009 Liposomal Gel
Sponsors: HanAll BioPharma Co., Ltd.; HanAll BioPharma Co., Ltd.
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: ARRY-502, CRTh2 antagonist; oral; Drug: Placebo; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Primatene Mist; Drug: Epinephrine inhalation aerosol, HFA; Drug: epinephrine inhalation aerosol
Sponsors: Amphastar Pharmaceuticals, Inc.; Amphastar Pharmaceuticals, Inc.
Recruiting - verified November 2011 - Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Conditions: Atopic Dermatitis; Eczema Herpeticum
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Asthma
Intervention: Drug: Epinephrine Inhalation Aerosol
Sponsors: Amphastar Pharmaceuticals, Inc.; Amphastar Pharmaceuticals, Inc.
Recruiting - verified October 2011 - Condition: Seasonal Allergic Rhinitis
Interventions: Drug: Ciclesonide nasal aerosol 37 mcg; Drug: ciclesonide nasal aerosol 74 mcg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Conditions: Perennial Allergic Rhinitis; PAR
Interventions: Drug: Ciclesonide nasal aerosol 37 mcg; Drug: ciclesonide nasal aerosol 74 mcg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: QAW039; Drug: Comparator leukotriene receptor antagonist (LRTA); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Asthma
Intervention: Drug: Tralokinumab
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified January 2012 - Condition: Atopic Dermatitis
Interventions: Other: Cetaphil Restoraderm; Other: Standard of Care
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Galderma
Recruiting - verified June 2011 - Condition: Asthma
Interventions: Biological: SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified April 2012 - Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Reslizumab; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified April 2012 - Condition: Dermatitis
Interventions: Biological: REGN668; Biological: REGN668; Biological: REGN668
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified February 2012 - Condition: Hereditary Angioedema
Interventions: Drug: rhC1INH; Drug: Placebo (Saline)
Sponsors: Pharming Technologies B.V.; Pharming Technologies B.V.
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: budesonide; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2012 - Condition: Hereditary Angioedema
Intervention: Biological: Cinryze
Sponsors: ViroPharma; ViroPharma
Recruiting - verified April 2011 - Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012
 |
Join Clinical Trials in Oregon for Allergies |
